查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715655

肝病診斷市場（按產品、疾病類型和最終用戶分類）—2025-2030 年全球預測

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2024 年肝病診斷市場規模將達到 110.9 億美元，到 2025 年將達到 125.7 億美元，到 2030 年將達到 230.8 億美元，複合年成長率為 12.99%。

主要市場統計數據
基準年2024年 110.9億美元
預計2025年 125.7億美元
預測年份 2030 230.8億美元
複合年成長率（%） 12.99%

在快速發展的肝病診斷領域，創新和精確比以往任何時候都更重要。本報告深入探討了改變肝病診斷和治療方法的變化。報告首先清楚地闡述了推動產業向更準確、更可靠、更少侵入性的診斷方法發展的市場動態。關鍵促進因素包括技術進步、臨床方法的不斷改進以及對早期檢測和個人化治療計劃的需求不斷增加。

本分析採用整體視角，有系統地探討影響市場動態的最新趨勢、新興挑戰和突破性發展。肝病是全球面臨的重大健康挑戰，加強診斷通訊協定對於減少嚴重後果和最佳化患者照護至關重要。這項全面的介紹為後續章節奠定了基礎，包括各種細分考慮、區域分析、競爭格局和可行的建議，旨在為決策者和行業專家提供新興的商業機會和策略必要事項。

肝病診斷市場的轉型

近年來，由於技術的快速進步和臨床方法的不斷發展，肝病診斷領域發生了顯著變化。診斷影像和微創手術的重大創新徹底改變了肝病的檢測方式。人們越來越重視生物標記的開發以及人工智慧和診斷成像的整合，這對於提高診斷的準確性和速度至關重要。曾經嚴重依賴傳統影像的調查方法現在得到了尖端血液測試和先進內視鏡手術的補充。

隨著臨床實踐的發展，新切片檢查技術的採用正在提高患者的安全性和診斷的可靠性。這種演變也回應了日益成長的早期檢測需求，其中簡化的流程和更短的手術時間受到高度重視。數位健康解決方案與傳統診斷方法之間的協同效應將實現無縫的患者體驗，使醫療保健提供者更容易監測後續觀察和病情進展。

這些變革趨勢不僅重塑了臨床工作流程，而且還影響了醫療保健相關人員的更廣泛策略。透過適應這種不斷變化的形勢，行業相關人員可以提供可自訂的綜合診斷解決方案，滿足患者的特定需求，最終改善臨床結果。

肝病診斷的關鍵細分洞察

在了解肝病診斷市場時，關鍵的細分洞察是支柱。第一次細分是透過各種診斷方法來細分市場。在切片檢查技術領域，已經探索了腹腔鏡、經皮和經靜脈方法，每種方法都旨在平衡侵入性和診斷準確性。同樣，血液檢查側重於各種酶的評估，例如丙氨酸轉氨酶、天冬氨酸轉氨酶和γ-谷氨醯轉肽酶測試，以提供對肝功能和肝損傷的細緻了解。同時，在影像診斷方面，我們將深入研究不同精確度的檢查方式，包括電腦斷層掃描、MRI 和超音波。

第二個細分捕捉疾病的類型，從急性肝炎和酒精性肝病到慢性肝炎、肝硬化、肝細胞癌和非酒精性脂肪肝病。透過這種維度分析，我們可以深入了解每種肝病的診斷挑戰和資源需求。最後，基於最終用戶的細分檢驗了診斷實驗室、醫院和研究機構中診斷技術的多樣化部署。每個細分不僅揭示了臨床和業務動態，還揭示了不同垂直市場中的技術部署和業務成長機會。

這些市場區隔洞察可以為相關人員提供清晰的思路，使他們能夠瞄準市場中的特定領域，完善產品系列，並調整策略舉措，以應對頻譜肝臟相關疾病中獨特的診斷挑戰。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 認知到肝臟診斷的需求日益成長以及早期診斷的努力
      • 醫療成本的上漲促使對肝病診斷服務的投資增加
      • 全球性肝病的發生率不斷上升，對診斷的需求也隨之增加。
    • 限制因素
      • 先進診斷程序高成本
    • 機會
      • 技術進步促進了更準確、侵入性更小的診斷方法的發展
      • 人們對遠距肝病監測和診斷的遠端醫療解決方案的興趣日益濃厚
    • 任務
      • 新診斷工具的監管更加嚴格，核准流程也更加冗長
  • 市場區隔分析
    • 圖片來源：內視鏡檢查在食道靜脈曲張的檢測和治療中的重要性日益增加
    • 最終用戶：醫院擴大採用肝病診斷來提供即時檢測和干涉策略
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章肝病診斷市場（按類型）

  • 切片檢查技術
    • 腹腔鏡切片檢查
    • 經皮肝切片檢查
    • 靜脈肝切片檢查
  • 血液檢查
    • 丙氨酸轉氨酶檢測
    • 天門冬胺酸轉氨酶檢測
    • γ-谷氨醯轉肽酶檢測
  • 內視鏡檢查
  • 影像學診斷
    • 電腦斷層掃描
    • MRI
    • 超音波

第7章肝病診斷市場（依疾病類型）

  • 急性肝炎
  • 酒精性肝臟疾病
  • 慢性肝炎
  • 肝硬化
  • 肝細胞癌
  • 非酒精性脂肪肝

第8章肝病診斷市場（按最終用戶）

  • 診斷實驗室
  • 醫院
  • 研究組織

9.美洲肝病診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10.亞太地區肝病診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 11 章歐洲、中東和非洲肝病診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Amgen Inc.
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Boston Scientific Corporation
  • Cook Medical Incorporated
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hepatiq, Inc.
  • Hologic, Inc.
  • Horiba, Ltd.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Perspectum Ltd.
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Ri.Mos. Srl
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-B9334AD6C587

The Liver Disease Diagnostics Market was valued at USD 11.09 billion in 2024 and is projected to grow to USD 12.57 billion in 2025, with a CAGR of 12.99%, reaching USD 23.08 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 11.09 billion
Estimated Year [2025] USD 12.57 billion
Forecast Year [2030] USD 23.08 billion
CAGR (%) 12.99%

In the rapidly evolving realm of liver disease diagnostics, innovation and precision are more critical than ever. This report offers a deep dive into the transformative shifts reshaping how liver disorders are diagnosed and managed. The discussion begins with a clear articulation of prevailing market dynamics that are steering industry evolution towards more accurate, reliable, and less invasive diagnostic procedures. Key drivers include advances in technology, a continuous refinement in clinical practices, and the growing demand for early-stage detection coupled with personalized treatment plans.

The analysis takes a holistic view, systematically exploring the latest trends, emerging challenges, and breakthrough developments influencing market behavior. With liver disease presenting a significant health challenge globally, enhanced diagnostic protocols are critical in mitigating severe outcomes and optimizing patient care. This comprehensive introduction sets the stage for the subsequent sections that navigate through various segmentation insights, regional analyses, the competitive landscape, and actionable recommendations, all crafted to inform decision-makers and industry experts on emerging opportunities and strategic imperatives.

Transformative Shifts in the Liver Disease Diagnostics Landscape

Recent years have witnessed transformative shifts across the liver disease diagnostics landscape, driven by rapid technological advancements and evolving clinical approaches. Significant innovations in imaging modalities and minimally invasive procedures have revolutionized detection methods. There is an increasing emphasis on developing biomarkers and integrating artificial intelligence with diagnostic imaging, which has been critical in enhancing the accuracy and speed of diagnoses. Methodologies that once relied heavily on traditional imaging are now being complemented by state-of-the-art blood-based tests and sophisticated endoscopic procedures.

As clinical practices evolve, the adoption of novel biopsy techniques has improved both patient safety and diagnostic reliability. This evolution is also a response to the escalating demand for early detection, where streamlined processes and reduced procedure times are highly valued. The synergy between digital health solutions and traditional diagnostic methods enables a seamless patient experience, making it easier for health care providers to conduct follow-ups and monitor disease progression.

These transformative trends are not only reshaping clinical workflows but also influencing the broader strategies of healthcare stakeholders. By embracing this landscape of change, industry participants are better positioned to deliver integrated diagnostic solutions that are customizable and responsive to patient-specific needs, ultimately driving enhanced clinical outcomes.

Key Segmentation Insights in Liver Disease Diagnostics

Critical segmentation insights form the backbone of understanding the liver disease diagnostics market. The first segmentation focuses on offerings, segmenting the market through diverse diagnostic methods. In the realm of biopsy techniques, the investigation spans laparoscopic, percutaneous, and transvenous approaches, each crafted to balance invasiveness with diagnostic accuracy. Similarly, blood-based tests are dissected by focusing on different enzyme assessments that include alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase tests, providing nuanced insights into liver function and damage. Meanwhile, imaging diagnostics are evaluated by delving into modalities such as CT scans, MRI, and ultrasound, which offer varying levels of precision and are integral in both acute and chronic assessments.

The second segmentation captures disease types, ranging from acute hepatitis and alcoholic liver disease to chronic hepatitis, cirrhosis, hepatocellular carcinoma, and non-alcoholic fatty liver disease. This dimensional analysis ensures that each liver condition is explored in terms of its unique diagnostic challenges and resource requirements. Lastly, segmentation based on end-users provides an examination of the varied deployment of diagnostic technologies across diagnostic laboratories, hospitals, and research institutes. Each segment not only highlights distinct clinical and operational dynamics but also reveals tailored opportunities for technology deployment and business growth in different market verticals.

These segmentation insights collectively empower stakeholders with the clarity needed to target specific niches within the market, refine product portfolios, and align strategic initiatives to address unique diagnostic challenges across the spectrum of liver-related diseases.

Based on Offering, market is studied across Biopsy Techniques, Blood-Based Tests, Endoscopy, and Imaging Diagnostics. The Biopsy Techniques is further studied across Laparoscopic Liver Biopsy, Percutaneous Liver Biopsy, and Transvenous Liver Biopsy. The Blood-Based Tests is further studied across Alanine Transaminase Test, Aspartate Transaminase Test, and Gamma-Glutamyl Transpeptidase Test. The Imaging Diagnostics is further studied across CT Scan, MRI, and Ultrasound.

Based on Disease Type, market is studied across Acute Hepatitis, Alcoholic Liver Disease, Chronic Hepatitis, Cirrhosis, Hepatocellular Carcinoma, and Non-Alcoholic Fatty Liver Disease.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Research Institutes.

Assessing Regional Variations in Liver Disease Diagnostics

A regional assessment of the liver disease diagnostics market reveals significant geographic variations that influence market dynamics and growth trajectories. In the Americas, robust healthcare infrastructures and a pronounced focus on early disease detection have paved the way for the adoption of advanced diagnostic modalities. The region also benefits from extensive research and development investments, driving innovations that are rapidly integrated into clinical practices.

Across Europe, the Middle East, and Africa, diverse healthcare systems and regulatory frameworks have resulted in a dynamic, albeit fragmented, market landscape. Here, the interplay of governmental policies, reimbursement strategies, and regional disease prevalence creates both challenges and opportunities for diagnostic technology manufacturers. In these regions, collaborations between public and private healthcare providers are instrumental in facilitating the diffusion of diagnostic innovations.

The Asia-Pacific region presents a contrast, characterized by burgeoning healthcare markets, a large patient pool, and an increasing prevalence of lifestyle-related liver conditions. The region's rapid economic development and shifting disease patterns are compelling market players to adapt their strategies to meet the rising demand for cutting-edge diagnostic services. An increased focus on healthcare accessibility, combined with ongoing investments in medical technology facilities, is gradually transforming the diagnostic landscape in Asia-Pacific into one of the most vibrant and competitive globally.

These regional insights underscore the importance of tailored marketing strategies and localized product development to effectively respond to unique regional dynamics and optimize market penetration.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Leading Companies in Liver Disease Diagnostics

The competitive landscape in liver disease diagnostics is marked by robust innovation and strategic maneuvering by key market players. Leading companies have distinguishably played catalytic roles in shaping this market by deploying state-of-the-art diagnostic solutions and continuously refining their product portfolios. Prominent industry players such as Abbott Laboratories, Amgen Inc., and Argon Medical Devices, Inc. are at the forefront, leveraging expansive research networks and advanced technologies to secure competitive advantages.

Other influential companies include Bayer AG, Becton, Dickinson and Company, and Bio-Rad Laboratories, Inc. Their strategic focus on integrating diagnostic tests with streamlined clinical procedures has significantly reduced the turnaround time in diagnosing liver conditions. BioMerieux SA, Boston Scientific Corporation, and Cook Medical Incorporated have also cemented their positions through continuous innovation, backed by extensive clinical validation studies and rigorous R&D initiatives.

The market has further been invigorated by the contributions of Epigenomics AG and F. Hoffmann-La Roche Ltd., whose efforts in precision diagnostics are well recognized. Companies such as Fujifilm Holdings Corporation, Hepatiq, Inc., and Hologic, Inc. continue to expand their technological capabilities by forging strategic partnerships and investing in next-generation diagnostic platforms. Horiba, Ltd., Koninklijke Philips N.V., and Laboratory Corporation of America Holdings have demonstrated a consistent trajectory of growth by focusing on market-specific demands that encompass both chronic and acute liver disease diagnostics.

Recognized leaders in the field such as Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, and Randox Laboratories Ltd. further underscore the market's competitive intensity. Companies including Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. finalize this comprehensive roster of industry trailblazers, each contributing significantly to the evolution of diagnostic procedures with their dynamic range of product offerings and pioneering solutions in the liver disease diagnostics arena.

The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.. Strategic Recommendations for Industry Leaders

For industry leaders looking to navigate the dynamic and competitive landscape of liver disease diagnostics, several strategic recommendations can be drawn from emerging trends and market insights. Leaders are encouraged to focus on research and development initiatives that prioritize precision and minimally invasive diagnostic techniques. Investing in technologies that synergistically combine imaging modalities, blood-based tests, and biopsy techniques can significantly enhance diagnostic accuracy and improve patient outcomes.

Another key recommendation is to cultivate robust partnerships with research institutes and hospitals. This collaborative approach not only broadens the scope of clinical trials but also accelerates the adoption of new diagnostic methods. Aligning product innovation with regional market needs, particularly in rapidly growing areas like Asia-Pacific, ensures that solutions are both relevant and timely.

Industry players should also consider diversifying their product offerings to address the multifaceted nature of liver diseases. The market calls for an integrated approach that spans from acute to chronic conditions, and offering segmented solutions for different disease types is imperative. Furthermore, maintaining transparency around clinical efficacy and regulatory compliance will strengthen stakeholder trust and drive market acceptance.

Finally, leveraging digital health platforms to streamline patient data and integrate real-time analytics will empower stakeholders with actionable insights, thereby fostering a proactive rather than reactive approach in disease management. These recommendations collectively form a blueprint aimed at sustaining competitive advantage and fostering long-term growth in the liver disease diagnostics market.

Conclusion: Shaping the Future of Liver Disease Diagnostics

In conclusion, the liver disease diagnostics market stands at a pivotal juncture, characterized by significant technological advancements, evolving segmentation insights, and diverse regional dynamics. The comprehensive examination of offering-based segmentation, disease-specific demands, and end-user needs reveals a market that is both complex and ripe with opportunity. Embracing transformative shifts, such as the integration of digital health tools and the adoption of advanced diagnostic techniques, has set the foundation for enhanced clinical outcomes.

The competitive landscape, driven by innovation from top companies, underscores the importance of continuous improvement and strategic agility. By aligning product development with evolving patient needs and regulatory environments, industry leaders can effectively address the challenges inherent in diagnosing liver diseases and drive superior value for healthcare providers and patients alike.

Taken together, the insights and data presented in this report provide a nuanced understanding of the current and future trends in liver disease diagnostics. The path ahead is filled with both challenges and opportunities that, when navigated effectively, can lead to groundbreaking advancements and improved healthcare outcomes across the globe.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and early diagnosis initiatives expanding the need for liver diagnostics
      • 5.1.1.2. Rising healthcare expenditure contributing to improved investment in liver disease diagnostic services
      • 5.1.1.3. Rising prevalence of liver diseases globally which is increasing the demand for diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of advanced diagnostic procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements contributing to the development of more precise and less invasive diagnostic methods
      • 5.1.3.2. Growing interest in telehealth solutions for remote liver disease monitoring and diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Stricter regulations and lengthy approval process for new diagnostic tools
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising significance of endoscopy for detecting and managing esophageal varices
    • 5.2.2. End-User: Growing adoption of liver disease diagnostics in hospitals to offer immediate testing and intervention strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Liver Disease Diagnostics Market, by Offering

  • 6.1. Introduction
  • 6.2. Biopsy Techniques
    • 6.2.1. Laparoscopic Liver Biopsy
    • 6.2.2. Percutaneous Liver Biopsy
    • 6.2.3. Transvenous Liver Biopsy
  • 6.3. Blood-Based Tests
    • 6.3.1. Alanine Transaminase Test
    • 6.3.2. Aspartate Transaminase Test
    • 6.3.3. Gamma-Glutamyl Transpeptidase Test
  • 6.4. Endoscopy
  • 6.5. Imaging Diagnostics
    • 6.5.1. CT Scan
    • 6.5.2. MRI
    • 6.5.3. Ultrasound

7. Liver Disease Diagnostics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Acute Hepatitis
  • 7.3. Alcoholic Liver Disease
  • 7.4. Chronic Hepatitis
  • 7.5. Cirrhosis
  • 7.6. Hepatocellular Carcinoma
  • 7.7. Non-Alcoholic Fatty Liver Disease

8. Liver Disease Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Research Institutes

9. Americas Liver Disease Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Liver Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Liver Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Argon Medical expands liver diagnostics portfolio with innovative device launches
    • 12.3.2. Apollo hospitals unveils advanced fatty liver clinic with innovative diagnostic and treatment solutions
    • 12.3.3. Quibim unveils QP-liver for enhanced AI-driven diagnosis of diffuse liver diseases
    • 12.3.4. E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
    • 12.3.5. Stone Diagnostics to Provide Fibronostics Liver Disease Test
    • 12.3.6. Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. Argon Medical Devices, Inc.
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioMerieux SA
  • 8. Boston Scientific Corporation
  • 9. Cook Medical Incorporated
  • 10. Epigenomics AG
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Fujifilm Holdings Corporation
  • 13. Hepatiq, Inc.
  • 14. Hologic, Inc.
  • 15. Horiba, Ltd.
  • 16. Koninklijke Philips N.V.
  • 17. Laboratory Corporation of America Holdings
  • 18. Medtronic PLC
  • 19. Merck & Co., Inc.
  • 20. Perspectum Ltd.
  • 21. Quest Diagnostics Incorporated
  • 22. Randox Laboratories Ltd.
  • 23. Ri.Mos. Srl
  • 24. Siemens Healthineers AG
  • 25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. LIVER DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
  • FIGURE 2. LIVER DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. LIVER DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 4. LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 286. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024